• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$9.40 $0.32 (3.52%)

REAL-TIME: Last trade at

Gentium S.p.A. (ADR)

NASDAQ:GENT

Gentium reports Q1 EPS EUR(6c) vs. EUR(11c)

Gentium Reports First Quarter Financial Results

Gentium gets Day 180 list of outstanding issues from CHMP for Defibrotide

Gentium appoints PharmaSwiss exclusive distributor of Defibrotide in Europe

Gentium initiated with a Buy at Brean Murray

Gentium Hosts Symposium on Defibrotide at EBMT Annual Meeting

Gentium Reports Fourth Quarter and Year End 2011 Financial Results

Gentium to Review Fourth Quarter and Year End 2011 Financial Results

Gentium Appoints Dr. Carin Heringa as Senior Vice President and Scientific Director

The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients

Gentium upgraded to Buy from Sell at ThinkEquity

Gentium responds to the EMA's day 120 list of questions for Defibrotide MAA

Gentium Responds to the EMA's Day 120 List of Questions for Defibrotide MAA

Gentium appoints Swedish Orphan Biovitrum as defibrotide exclusive distributor

Gentium Appoints Swedish Orphan Biovitrum AB as Exclusive Distributor of Defibrotide in Nordic and Baltic Territories

Gentium provides update on MAA process for Defibrotide in Europe

Gentium Provides Update on MAA Process for Defibrotide in Europe

Gentium presents results from study of Defibrotide

Results From Gentium's Treatment IND for Defibrotide Presented at the American Society of Hematology Annual Meeting

Gentium Announces Changes to Board of Directors

Gentium falls 8.2%

Updated Results From Gentium's Treatment IND for Defibrotide to be Presented at the American Society of Hematology

Gentium Announces Establishment of Commercial Infrastructure and Appointment of Commercial Leadership Team

Gentium Reports Third Quarter 2011 Financial Results

Gentium updates on MAA process for Defibrotide in Europe

Gentium Provides Update on MAA Process for Defibrotide in Europe

Gentium makes management changes

Gentium Announces Management Change

Gentium Reports First Half 2011 Financial Results

Gentium to Review First Half 2011 Financial Results

The Worst Performing Stocks As The Market Tanks (C, IVR, JDSU, CIS, GENT, NTAP, APKT, RVBD, TYH, MGM, EMC, BAC, ORCL)

Gentium falls 30.8%

Pre-market Movers For Aug 18 (CNX, PERY, LTD, KO, CELG, NTAP, GENT, MGM, SHLD)

Top Active Trader Alerts (CBOU, GENT, IVR, JASO, JDSU, NTAP, SINA, BCS, LYG, CS, ALU)

After-market Movers For Aug 17 (BA, LTD, CREE, CACI, NTAP, PETM, GENT, WILN)

After-Hours Stocks on the Move (HOTT, IVR, JDSU, LTD, NTAP, PETM, SNPS, GENT)

Gentium announces voluntarily withdraw of Defibrotide application

Gentium Withdraws New Drug Application for Defibrotide

Italy's a Mess

Gentium initiated with a Buy at ThinkEquity

See More Articles...